1. Verlinden, L., Verstuyf, A., Quack, M., van
Camp, M., van Etten, E., De Clercq, P., Vandewalle, M., Carlberg, C.
and Bouillon, R. Interaction of two novel 14-epi-vitamin D3 analogs with
vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3
responsive elements. (2001) J. Bone Miner. Res., 16, 625-638 (Impact
factor2001 6.2). PDF-FILE
2. Bury, Y., Ruf, D., Mørk Hansen, C., Kissmeyer, A.-M., Binderup, L. and
Carlberg, C. Molecular evaluation of vitamin D3 receptor agonists
designed for a topical treatment of skin diseases. (2001) J. Invest.
Dermatol., 116, 785-792 (Impact factor2001 4.6).
PDF-FILE
3. Toell, A., Macias-Gonzalez, M., Ruf, D., Steinmeyer, A., Ishizuka, S.
and Carlberg, C. Different molecular mechanisms of vitamin D3
receptor antagonists (2001) Mol. Pharmacol., 59, 1478-1485 (Impact
factor2001 5.9). PDF-FILE
4. Bury, Y., Herdick, M., Uskokovic, M.R. and Carlberg, C. Gene
regulatory potential of 1a,25-dihydroxyvitamin D3 analogues with two side
chains. (2001) J. Cell Biochem., 81(S36), 179-190 (Impact factor2001
2.5). PDF-FILE
5. Lampen, A., Carlberg, C. and Nau, H. Peroxisome
proliferator-activated receptor d is a specific sensor for teratogenic
valproic acid derivatives. (2001) Eur. J. Pharmacol. 431, 25-33 (Impact
factor2001 2.2). PDF-FILE
6. Quack, M. and Carlberg, C. Single thyroid hormone receptor
monomers are competent for coactivator-mediated transactivation. (2001)
Biochem. J. 360, 387-393 (Impact factor2001 4.3).
PDF-FILE |
|
|
|
